Loading...
27 acetaminophen COVID-19 controlled studies, 2 RCTs
https://c19early.org/acemeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Rinott -473% 5.73 [0.30-109] death 3/85 0/49 OT1 Improvement, RR [CI] Treatment Control Rinott -534% 6.34 [0.84-47.6] oxygen 11/85 1/49 OT1 Lapi (ES) -15% 1.15 [0.92-1.43] death/hosp. n/a n/a Lapi (ES) -29% 1.29 [0.61-2.73] death/hosp. n/a n/a Sharif -77% 1.77 [0.39-8.09] death 9/361 2/142 Chen -32% 1.32 [0.98-1.78] PASC 98/232 39/122 LONG COVID Chen -1% 1.01 [0.67-1.52] PASC 16/41 121/313 LONG COVID Ravichandran (PSM) -2700% 28.00 [3.91-200] oxygen 28/72 1/72 OT1 Ravichandran -75% 1.75 [1.48-2.06] recov. time 72 (n) 72 (n) OT1 Ravichandran -117% 2.17 [1.72-2.72] recov. time 72 (n) 72 (n) OT1 Ravichandran -167% 2.67 [2.00-3.56] recov. time 72 (n) 72 (n) OT1 Manjani -220% 3.20 [1.51-6.82] death 64/388 7/136 Manjani -434% 5.34 [1.98-14.4] ventilation 388 (n) 136 (n) Manjani -244% 3.44 [1.49-8.54] progression 132 (n) 136 (n) Manjani -201% 3.01 [1.40-7.07] progression 256 (n) 136 (n) Manjani -100% 2.00 [1.33-3.02] hosp. time 388 (n) 136 (n) Lerner -27% 1.27 [0.96-1.68] death 5,783 (all patients) Ravichandran (RCT) -43% 1.43 [1.14-1.78] no recov. 77/107 52/103 OT1 Ravichandran (RCT) -3925% 40.25 [2.47-657] progression 20/107 0/103 OT1 Ravichandran (RCT) -133% 2.33 [1.82-3.00] recov. time 107 (n) 103 (n) OT1 Ravichandran (RCT) -75% 1.75 [1.48-2.06] recov. time 107 (n) 103 (n) OT1 Ravichandran (RCT) -75% 1.75 [1.48-2.06] recov. time 107 (n) 103 (n) OT1 Ravichandran (RCT) -20% 1.20 [0.93-1.56] viral+ 43/60 37/62 OT1 Lapi -75% 1.75 [1.40-2.18] death/hosp. n/a n/a Abolhassani -56% 1.56 [0.58-4.18] death 3/6 8/25 Baldia (ICU) 12% 0.88 [0.72-1.07] death 1,166 (n) 1,480 (n) ICU patients Baldia (ICU) 14% 0.86 [0.72-1.03] death 1,166 (n) 1,480 (n) ICU patients Stufano -19% 1.19 [0.70-2.02] PASC 11/23 23/57 Sobhy (DB RCT) -110% 2.10 [1.05-4.20] ICU 21/90 10/90 OT1 Sobhy (DB RCT) -110% 2.10 [1.05-4.20] oxygen 21/90 10/90 OT1 Sobhy (DB RCT) -36% 1.36 [1.07-1.73] hosp. time 90 (n) 90 (n) OT1 Sobhy (DB RCT) -33% 1.33 [0.31-5.79] no recov. 4/90 3/90 OT1 Sobhy (DB RCT) -75% 1.75 [0.77-3.97] no recov. 14/90 8/90 OT1 Sobhy (DB RCT) -92% 1.92 [1.05-3.52] no recov. 25/90 13/90 OT1 Sobhy (DB RCT) -70% 1.70 [1.06-2.72] no recov. 34/90 20/90 OT1 Blanc -51% 1.51 [0.82-2.84] cases 60 (n) 119 (n) Kolin -23% 1.23 [1.05-1.43] cases 397,064 (all patients) Park (PSM) 25% 0.75 [0.35-1.59] death 12/397 16/397 OT1 Park (PSM) 38% 0.62 [0.19-1.89] ventilation 5/397 8/397 OT1 Gálvez-Barrón -47% 1.47 [0.66-3.33] death 43 (n) 60 (n) Gálvez-Barrón 23% 0.77 [0.35-1.71] severe case 43 (n) 60 (n) Reese (PSM) -61% 1.61 [1.40-1.84] death 20,826 (n) 20,826 (n) Reese (PSM) -816% 9.16 [8.72-9.63] severe case 20,826 (n) 20,826 (n) Chandan (PSM) -18% 1.18 [0.83-1.64] death 71/8,595 79/8,595 OT1 CT2 Chandan (PSM) -27% 1.27 [0.90-1.75] cases 8,595 (n) 8,595 (n) OT1 CT2 Oh 2% 0.98 [0.38-2.49] death 58 (n) 7,655 (n) Leal 7% 0.93 [0.91-0.96] cases n/a n/a Moreno-Martos -29% 1.29 [1.27-1.32] hosp. Moreno-Martos -52% 1.52 [1.28-1.79] hosp. 103/178 196/514 Moreno-Martos -5% 1.05 [0.91-1.22] hosp. 87/144 360/626 Moreno-Martos 22% 0.78 [0.63-0.98] hosp. 64/319 1,585/6,181 Moreno-Martos -16% 1.16 [1.13-1.20] hosp. Moreno-Martos -57% 1.57 [1.50-1.65] hosp. 1,090/1,868 3,414/9,188 Moreno-Martos -47% 1.47 [1.40-1.54] hosp. 1,397/2,875 3,214/9,735 MacFadden -48% 1.48 [1.44-1.51] cases n/a n/a Campbell (PSW) -1% 1.01 [0.99-1.02] death 2,074 (n) 20,311 (n) Campbell (PSW) 0% 1.00 [0.99-1.02] death 2,074 (n) 20,311 (n) Xie -5% 1.05 [0.70-1.56] hosp. population-based cohort OT1 Xie 3% 0.97 [0.72-1.29] cases population-based cohort OT1 Kim (PSM) -71% 1.71 [0.69-4.24] death 12/162 7/162 OT1 Kim (PSM) -14% 1.14 [0.42-3.08] ventilation 8/162 7/162 OT1 Kim (PSM) 40% 0.60 [0.15-2.47] ICU 3/162 5/162 OT1 Kim (PSM) -9% 1.09 [0.64-1.86] oxygen 24/162 22/162 OT1 Ritsinger -21% 1.21 [1.17-1.25] death 24,641 (n) 20,225 (n) Acetaminophen COVID-19 outcomes c19 earlyNovember 2023 1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors acetaminophen Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of over 100,000 datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Vaccines and treatments are complementary. All practical, effective, and safe
means should be used based on risk/benefit analysis. No treatment, vaccine, or
intervention is 100% available and effective for all current and future
variants. We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
